Spotlight on: Prostate Cancer
Every year around 10,000 men in Sweden receive the diagnosis of prostate cancer, and the number of Swedish men who die from the disease is around 2,500. This makes prostate cancer the most common and deadliest cancer form in the country. Researchers are struggling to find ways of preventing the disease. Another challenge is to develop safe methods of diagnostics.
The search for definite answers
Many researchers agree that screening is a way to reduce mortality in prostate cancer patients, but so far the diagnostic methods have been inadequate. The researchers are working to improve the accuracy of diagnoses, and they are enlisting help from areas such as AI.
Peter: “One day I will die”
For Peter Örn, the prostate cancer became a way to confront his own mortality and begin to appreciate the little things in life.
Hans: “Yoga has helped me”
When the side effects of the treatment against prostate cancer put an end to Hans Joelsson's active lifestyle, yoga became an alternative.
Christina: "Will he survive?”
When Christina Örum's partner was diagnosed with prostate cancer the couple had to deal with many challenges.
That is why the issue of a PSA test is not so simple
The test that is currently used in Sweden to test for prostate cancer is the so-called PSA test. It is easy to take, but the consequences of it can be trying.
The ProBio Project
This is an international, multi-centre platform trial in men with de novo metastatic hormone-sensitive (mHSPC) or metastatic castration-resistant (mCRPC) prostate cancer.
The STHLM3 study
Men who are being investigated for prostate cancer face difficult dilemmas. The STHLM3 study is a EU funded project with the aim of developing safer diagnostics.
Finding treatments for metastatic prostate cancer
Professor Emeritus Sten Nilsson remembers when he administered the trial preparation to treat metastatic prostate cancer to the very first patient. "It was with a feeling of curiosity and anticipation, mixed with the weight of the gravity of the moment," he says.